Jae Rock Do1, Hwa Lee2, Sehyun Baek2, Tae Soo Lee3, Minwook Chang4. 1. Department of Ophthalmology, Dongguk University Ilsan Hospital, 814, Siksadong, Ilsan-dong-gu, Koyang, Kyunggido, South Korea, 410-773. 2. Department of Ophthalmology, Korea University College of Medicine, Seoul, Korea. 3. Department of Ophthalmology, Nune Eye Hospital, Seoul, Republic of Korea. 4. Department of Ophthalmology, Dongguk University Ilsan Hospital, 814, Siksadong, Ilsan-dong-gu, Koyang, Kyunggido, South Korea, 410-773. mdjacob@dumc.or.kr.
Abstract
PURPOSE: To evaluate the effect of postoperative topical mitomycin-C (MMC) eye drops in endoscopic (dacryocystorhinostomy) DCR and compare them with intraoperative MMC soaking. DESIGN: Retrospective, nonrandomized, interventional case series. METHODS: One hundred and sixty cases of endoscopic DCR with a single surgeon for primary nasolacrimal duct obstruction (NLDO) were included. Cases were divided into three groups. Group 1 was treated with intraoperative application of 0.02 % MMC for 5 min. Group 2 was treated with 0.02 % MMC eye drops for 5 days after surgery, without intraoperative application of MMC. Group 3 was the control group of cases without the use of MMC. Each group was evaluated for surgical success, presence of complications including granuloma, synechiae, and tube-induced inflammation, and the adverse effect of the MMC at least 6 months after the surgery. RESULTS: The success rate showed no significant difference among the three groups (P = .122, chi-square analysis). In the analysis between the two groups, although the success rate of Group 2 appeared not to be statistically different compared with that of Group 1 (P = .419, chi-square analysis), Group 2 had a statistically higher success rate for surgery than Group 3 (P = .041, chi-square analysis). The presence of granuloma was significantly lower in Group 1 than in the other two groups (P = .022, chi-square analysis). Synechiae and silicone tube-induced inflammation were not significantly different (P = .308, P = .881, chi-square analysis). There were no adverse effects associated with intraoperative or postoperative MMC application. CONCLUSION: Use of postoperative topical 0.02 % MMC is a safe and effective adjunctive modality to increase the success rate of endoscopic DCR.
PURPOSE: To evaluate the effect of postoperative topical mitomycin-C (MMC) eye drops in endoscopic (dacryocystorhinostomy) DCR and compare them with intraoperative MMC soaking. DESIGN: Retrospective, nonrandomized, interventional case series. METHODS: One hundred and sixty cases of endoscopic DCR with a single surgeon for primary nasolacrimal duct obstruction (NLDO) were included. Cases were divided into three groups. Group 1 was treated with intraoperative application of 0.02 % MMC for 5 min. Group 2 was treated with 0.02 % MMC eye drops for 5 days after surgery, without intraoperative application of MMC. Group 3 was the control group of cases without the use of MMC. Each group was evaluated for surgical success, presence of complications including granuloma, synechiae, and tube-induced inflammation, and the adverse effect of the MMC at least 6 months after the surgery. RESULTS: The success rate showed no significant difference among the three groups (P = .122, chi-square analysis). In the analysis between the two groups, although the success rate of Group 2 appeared not to be statistically different compared with that of Group 1 (P = .419, chi-square analysis), Group 2 had a statistically higher success rate for surgery than Group 3 (P = .041, chi-square analysis). The presence of granuloma was significantly lower in Group 1 than in the other two groups (P = .022, chi-square analysis). Synechiae and silicone tube-induced inflammation were not significantly different (P = .308, P = .881, chi-square analysis). There were no adverse effects associated with intraoperative or postoperative MMC application. CONCLUSION: Use of postoperative topical 0.02 % MMC is a safe and effective adjunctive modality to increase the success rate of endoscopic DCR.
Authors: J Frucht-Pery; J Sugar; J Baum; J E Sutphin; J Pe'er; H Savir; E J Holland; D M Meisler; J A Foster; R Folberg; Y Rozenman Journal: Ophthalmology Date: 1997-12 Impact factor: 12.079